Fundies. English
Segment disclosures
Company overviewBECTON, DICKINSON AND COMPANY
Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.
Revenue · Reported segment facts
171 dimension combinations 785 retained observations 9 reported periods Partial retained history
Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.
Advanced Patient Monitoring · Operating Segments · Medical
Organizational Unit · Consolidation Items · Statement Business Segments
Source dimensions
bdx:OrganizationalUnitAxis=bdx:AdvancedPatientMonitoringMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 257000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 528000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 74000000 | USD | 2024-11-27 · 18:36:08.000Z | Open filing evidence |
Biosciences · Operating Segments · Life Sciences
Organizational Unit · Consolidation Items · Statement Business Segments
Source dimensions
bdx:OrganizationalUnitAxis=bdx:BiosciencesMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 352000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 713000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 1512000000 | USD | 2024-11-27 · 18:36:08.000Z | Open filing evidence |
Diagnostic Solutions · Operating Segments · Life Sciences
Organizational Unit · Consolidation Items · Statement Business Segments
Source dimensions
bdx:OrganizationalUnitAxis=bdx:DiagnosticSolutionsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 440000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 914000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
Integrated Diagnostic Solutions · Operating Segments · Life Sciences
Organizational Unit · Consolidation Items · Statement Business Segments
Source dimensions
bdx:OrganizationalUnitAxis=bdx:IntegratedDiagnosticSolutionsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-10-01 – 2024-09-30 | 3679000000 | USD | 2024-11-27 · 18:36:08.000Z | Open filing evidence |
Medication Delivery Solutions · Operating Segments · Medical
Organizational Unit · Consolidation Items · Statement Business Segments
Source dimensions
bdx:OrganizationalUnitAxis=bdx:MedicationDeliverySolutionsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 1117000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 2241000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 4429000000 | USD | 2024-11-27 · 18:36:08.000Z | Open filing evidence |
Medication Management Solutions · Operating Segments · Medical
Organizational Unit · Consolidation Items · Statement Business Segments
Source dimensions
bdx:OrganizationalUnitAxis=bdx:MedicationManagementSolutionsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 811000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 1612000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 3297000000 | USD | 2024-11-27 · 18:36:08.000Z | Open filing evidence |
Peripheral Intervention · Operating Segments · Interventional
Organizational Unit · Consolidation Items · Statement Business Segments
Source dimensions
bdx:OrganizationalUnitAxis=bdx:PeripheralInterventionMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 481000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 954000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 1933000000 | USD | 2024-11-27 · 18:36:08.000Z | Open filing evidence |
Pharmaceutical Systems · Operating Segments · Medical
Organizational Unit · Consolidation Items · Statement Business Segments
Source dimensions
bdx:OrganizationalUnitAxis=bdx:PharmaceuticalSystemsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 575000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 993000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 2273000000 | USD | 2024-11-27 · 18:36:08.000Z | Open filing evidence |
Specimen Management · Operating Segments · Life Sciences
Organizational Unit · Consolidation Items · Statement Business Segments
Source dimensions
bdx:OrganizationalUnitAxis=bdx:SpecimenManagementMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 456000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 917000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
Surgery · Operating Segments · Interventional
Organizational Unit · Consolidation Items · Statement Business Segments
Source dimensions
bdx:OrganizationalUnitAxis=bdx:SurgeryMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 383000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 778000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 1492000000 | USD | 2024-11-27 · 18:36:08.000Z | Open filing evidence |
Urologyand Critical Care · Operating Segments · Interventional
Organizational Unit · Consolidation Items · Statement Business Segments
Source dimensions
bdx:OrganizationalUnitAxis=bdx:UrologyandCriticalCareMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 400000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 789000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 1554000000 | USD | 2024-11-27 · 18:36:08.000Z | Open filing evidence |
Operating Segments · Advanced Patient Monitoring · Connected Care
Consolidation Items · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:AdvancedPatientMonitoringMember;us-gaap:StatementBusinessSegmentsAxis=bdx:ConnectedCareMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 292000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2026-03-31 | 589000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2025-12-31 | 297000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 257000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 528000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 271000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
Operating Segments · Advanced Patient Monitoring · Medical
Consolidation Items · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:AdvancedPatientMonitoringMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-10-01 – 2025-09-30 | 1082000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 278000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 806000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 271000000 | USD | 2025-02-06 · 22:03:32.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 74000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 0 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 0 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
Operating Segments · Bio Pharma Systems · Bio Pharma Systems
Consolidation Items · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:BioPharmaSystemsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:BioPharmaSystemsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 590000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2026-03-31 | 1019000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2025-12-31 | 429000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 575000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 993000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 418000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
Operating Segments · Biosciences · Life Sciences
Consolidation Items · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:BiosciencesMember;us-gaap:StatementBusinessSegmentsAxis=bdx:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-10-01 – 2025-12-31 | 327000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2024-10-01 – 2025-09-30 | 1458000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 358000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 1071000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 361000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 1512000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 363000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 1115000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
Operating Segments · Biosciences · Life Sciences · US
Consolidation Items · Organizational Unit · Statement Business Segments · Statement Geographical
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:BiosciencesMember;us-gaap:StatementBusinessSegmentsAxis=bdx:LifeSciencesMember;srt:StatementGeographicalAxis=country:US| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-04-01 – 2024-06-30 | 141000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 426000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
Operating Segments · Diagnostic Solutions · Life Sciences
Consolidation Items · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:DiagnosticSolutionsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-10-01 – 2025-12-31 | 439000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2024-10-01 – 2025-09-30 | 1838000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 425000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 1340000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 474000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 1846000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 429000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 1365000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
Operating Segments · Integrated Diagnostic Solutions · Life Sciences
Consolidation Items · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:IntegratedDiagnosticSolutionsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-04-01 – 2024-06-30 | 896000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 2737000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
Operating Segments · Integrated Diagnostic Solutions · Life Sciences · US
Consolidation Items · Organizational Unit · Statement Business Segments · Statement Geographical
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:IntegratedDiagnosticSolutionsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:LifeSciencesMember;srt:StatementGeographicalAxis=country:US| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-04-01 – 2024-06-30 | 405000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 1286000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
Operating Segments · Medication Delivery Solutions · Medical Essentials
Consolidation Items · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:MedicationDeliverySolutionsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalEssentialsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 1163000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2026-03-31 | 2291000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2025-12-31 | 1128000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 1117000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 2241000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 1124000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
Operating Segments · Medication Delivery Solutions · Medical
Consolidation Items · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:MedicationDeliverySolutionsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-10-01 – 2025-09-30 | 4575000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 1132000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 3373000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 1124000000 | USD | 2025-02-06 · 22:03:32.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 4429000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 1123000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 3282000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
Operating Segments · Medication Delivery Solutions · Medical · US
Consolidation Items · Organizational Unit · Statement Business Segments · Statement Geographical
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:MedicationDeliverySolutionsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalMember;srt:StatementGeographicalAxis=country:US| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-04-01 – 2024-06-30 | 670000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 1971000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
Operating Segments · Medication Management Solutions · Connected Care
Consolidation Items · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:MedicationManagementSolutionsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:ConnectedCareMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 829000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2026-03-31 | 1663000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2025-12-31 | 835000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 811000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 1612000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 801000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
Operating Segments · Medication Management Solutions · Medical
Consolidation Items · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:MedicationManagementSolutionsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-10-01 – 2025-09-30 | 3474000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 888000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 2500000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 801000000 | USD | 2025-02-06 · 22:03:32.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 3297000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 840000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 2359000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
Operating Segments · Medication Management Solutions · Medical · US
Consolidation Items · Organizational Unit · Statement Business Segments · Statement Geographical
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:MedicationManagementSolutionsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalMember;srt:StatementGeographicalAxis=country:US| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-04-01 – 2024-06-30 | 680000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 1883000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
Operating Segments · Peripheral Intervention · Interventional
Consolidation Items · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:PeripheralInterventionMember;us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 515000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2026-03-31 | 1000000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2025-12-31 | 485000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2024-10-01 – 2025-09-30 | 1996000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 512000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 1466000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 481000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 954000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 473000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 1933000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 488000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 1431000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
Operating Segments · Pharmaceutical Systems · Medical
Consolidation Items · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:PharmaceuticalSystemsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-10-01 – 2025-09-30 | 2324000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 629000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 1622000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 418000000 | USD | 2025-02-06 · 22:03:32.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 2273000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 594000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 1596000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
Operating Segments · Pharmaceutical Systems · Medical · US
Consolidation Items · Organizational Unit · Statement Business Segments · Statement Geographical
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:PharmaceuticalSystemsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalMember;srt:StatementGeographicalAxis=country:US| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-04-01 – 2024-06-30 | 158000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 442000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
Operating Segments · Specimen Management · Life Sciences
Consolidation Items · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:SpecimenManagementMember;us-gaap:StatementBusinessSegmentsAxis=bdx:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-10-01 – 2025-09-30 | 1871000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 470000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 1387000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 462000000 | USD | 2025-02-06 · 22:03:32.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 1833000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 467000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 1372000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
Operating Segments · Specimen Management · Medical Essentials
Consolidation Items · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:SpecimenManagementMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalEssentialsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 484000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2026-03-31 | 951000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2025-12-31 | 468000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 456000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 917000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 462000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
Operating Segments · Surgery · Interventional
Consolidation Items · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:SurgeryMember;us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 411000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2026-03-31 | 829000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2025-12-31 | 418000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2024-10-01 – 2025-09-30 | 1572000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 395000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 1173000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 383000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 778000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 395000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 1492000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 376000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 1124000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
Operating Segments · Urologyand Critical Care · Interventional
Consolidation Items · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:UrologyandCriticalCareMember;us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 430000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2026-03-31 | 857000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2025-12-31 | 427000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2024-10-01 – 2025-09-30 | 1649000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 422000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 1211000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 400000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 789000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 389000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 1554000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 375000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 1165000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
Operating Segments · US · Advanced Patient Monitoring · Connected Care
Consolidation Items · Statement Geographical · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=country:US;bdx:OrganizationalUnitAxis=bdx:AdvancedPatientMonitoringMember;us-gaap:StatementBusinessSegmentsAxis=bdx:ConnectedCareMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 180000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2026-03-31 | 358000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2025-12-31 | 178000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 155000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 314000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 159000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
Operating Segments · US · Advanced Patient Monitoring · Medical
Consolidation Items · Statement Geographical · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=country:US;bdx:OrganizationalUnitAxis=bdx:AdvancedPatientMonitoringMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-10-01 – 2025-09-30 | 658000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 176000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 490000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 47000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 0 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 0 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
Operating Segments · US · Bio Pharma Systems · Bio Pharma Systems
Consolidation Items · Statement Geographical · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=country:US;bdx:OrganizationalUnitAxis=bdx:BioPharmaSystemsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:BioPharmaSystemsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 178000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2026-03-31 | 329000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2025-12-31 | 150000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 149000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 253000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 104000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
Operating Segments · US · Biosciences · Life Sciences
Consolidation Items · Statement Geographical · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=country:US;bdx:OrganizationalUnitAxis=bdx:BiosciencesMember;us-gaap:StatementBusinessSegmentsAxis=bdx:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-10-01 – 2025-12-31 | 124000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2024-10-01 – 2025-09-30 | 593000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 145000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 440000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 153000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 577000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 141000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 426000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
Operating Segments · US · Diagnostic Solutions · Life Sciences
Consolidation Items · Statement Geographical · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=country:US;bdx:OrganizationalUnitAxis=bdx:DiagnosticSolutionsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-10-01 – 2025-12-31 | 176000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2024-10-01 – 2025-09-30 | 755000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 154000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 556000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 212000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 782000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 167000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 578000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
Operating Segments · US · Medication Delivery Solutions · Medical Essentials
Consolidation Items · Statement Geographical · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=country:US;bdx:OrganizationalUnitAxis=bdx:MedicationDeliverySolutionsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalEssentialsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 712000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2026-03-31 | 1405000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2025-12-31 | 693000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 687000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 1381000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 694000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
Operating Segments · US · Medication Delivery Solutions · Medical
Consolidation Items · Statement Geographical · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=country:US;bdx:OrganizationalUnitAxis=bdx:MedicationDeliverySolutionsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-10-01 – 2025-09-30 | 2789000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 680000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 2060000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 2661000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 670000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 1971000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
Operating Segments · US · Medication Management Solutions · Connected Care
Consolidation Items · Statement Geographical · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=country:US;bdx:OrganizationalUnitAxis=bdx:MedicationManagementSolutionsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:ConnectedCareMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 660000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2026-03-31 | 1339000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2025-12-31 | 678000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 662000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 1321000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 659000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
Operating Segments · US · Medication Management Solutions · Medical
Consolidation Items · Statement Geographical · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=country:US;bdx:OrganizationalUnitAxis=bdx:MedicationManagementSolutionsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-10-01 – 2025-09-30 | 2810000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 709000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 2030000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 2627000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 680000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 1883000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
Operating Segments · US · Peripheral Intervention · Interventional
Consolidation Items · Statement Geographical · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=country:US;bdx:OrganizationalUnitAxis=bdx:PeripheralInterventionMember;us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 279000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2026-03-31 | 545000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2025-12-31 | 265000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2024-10-01 – 2025-09-30 | 1067000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 271000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 793000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 269000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 522000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 253000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 1029000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 263000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 762000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
Operating Segments · US · Pharmaceutical Systems · Medical
Consolidation Items · Statement Geographical · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=country:US;bdx:OrganizationalUnitAxis=bdx:PharmaceuticalSystemsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-10-01 – 2025-09-30 | 659000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 178000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 431000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 629000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 158000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 442000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
Operating Segments · US · Specimen Management · Life Sciences
Consolidation Items · Statement Geographical · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=country:US;bdx:OrganizationalUnitAxis=bdx:SpecimenManagementMember;us-gaap:StatementBusinessSegmentsAxis=bdx:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-10-01 – 2025-09-30 | 981000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 240000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 721000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 952000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 239000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 708000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
Operating Segments · US · Specimen Management · Medical Essentials
Consolidation Items · Statement Geographical · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=country:US;bdx:OrganizationalUnitAxis=bdx:SpecimenManagementMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalEssentialsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 253000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2026-03-31 | 498000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2025-12-31 | 245000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 242000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 481000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 238000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
Operating Segments · US · Surgery · Interventional
Consolidation Items · Statement Geographical · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=country:US;bdx:OrganizationalUnitAxis=bdx:SurgeryMember;us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 303000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2026-03-31 | 613000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2025-12-31 | 310000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2024-10-01 – 2025-09-30 | 1175000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 294000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 885000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 289000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 591000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 303000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 1130000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 283000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 851000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
Operating Segments · US · Urologyand Critical Care · Interventional
Consolidation Items · Statement Geographical · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=country:US;bdx:OrganizationalUnitAxis=bdx:UrologyandCriticalCareMember;us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 351000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2026-03-31 | 690000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2025-12-31 | 339000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2024-10-01 – 2025-09-30 | 1303000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 334000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 962000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 323000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 629000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 306000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 1236000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 297000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 930000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
Operating Segments · US · Connected Care
Consolidation Items · Statement Geographical · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=bdx:ConnectedCareMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 840000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2026-03-31 | 1697000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2025-12-31 | 857000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 817000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 1635000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 818000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
Operating Segments · US · Interventional
Consolidation Items · Statement Geographical · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 933000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2026-03-31 | 1847000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2025-12-31 | 914000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2024-10-01 – 2025-09-30 | 3545000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 898000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 2640000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 880000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 1742000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 861000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 3394000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 844000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 2543000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
Operating Segments · US · Life Sciences
Consolidation Items · Statement Geographical · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=bdx:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-10-01 – 2025-12-31 | 300000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2024-10-01 – 2025-09-30 | 2328000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 539000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 1717000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 365000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 2310000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 546000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 1712000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
Operating Segments · US · Medical Essentials
Consolidation Items · Statement Geographical · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalEssentialsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 965000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2026-03-31 | 1903000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2025-12-31 | 938000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 929000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 1861000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 932000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
Operating Segments · US · Medical
Consolidation Items · Statement Geographical · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-10-01 – 2025-09-30 | 6916000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 1743000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 5012000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 5964000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 1508000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 4297000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
Operating Segments · Non Us · Advanced Patient Monitoring · Connected Care
Consolidation Items · Statement Geographical · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;bdx:OrganizationalUnitAxis=bdx:AdvancedPatientMonitoringMember;us-gaap:StatementBusinessSegmentsAxis=bdx:ConnectedCareMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 112000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2026-03-31 | 231000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2025-12-31 | 119000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 102000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 215000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 113000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
Operating Segments · Non Us · Advanced Patient Monitoring · Medical
Consolidation Items · Statement Geographical · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;bdx:OrganizationalUnitAxis=bdx:AdvancedPatientMonitoringMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-10-01 – 2025-09-30 | 424000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 102000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 317000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 27000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 0 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 0 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
Operating Segments · Non Us · Bio Pharma Systems · Bio Pharma Systems
Consolidation Items · Statement Geographical · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;bdx:OrganizationalUnitAxis=bdx:BioPharmaSystemsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:BioPharmaSystemsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 411000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2026-03-31 | 690000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2025-12-31 | 279000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 426000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 740000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 314000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
Operating Segments · Non Us · Biosciences · Life Sciences
Consolidation Items · Statement Geographical · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;bdx:OrganizationalUnitAxis=bdx:BiosciencesMember;us-gaap:StatementBusinessSegmentsAxis=bdx:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-10-01 – 2025-12-31 | 202000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2024-10-01 – 2025-09-30 | 865000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 213000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 631000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 208000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 935000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 222000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 689000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
Operating Segments · Non Us · Diagnostic Solutions · Life Sciences
Consolidation Items · Statement Geographical · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;bdx:OrganizationalUnitAxis=bdx:DiagnosticSolutionsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-10-01 – 2025-12-31 | 264000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2024-10-01 – 2025-09-30 | 1083000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 271000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 783000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 262000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 1064000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 263000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 787000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
Operating Segments · Non Us · Medication Delivery Solutions · Medical Essentials
Consolidation Items · Statement Geographical · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;bdx:OrganizationalUnitAxis=bdx:MedicationDeliverySolutionsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalEssentialsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 451000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2026-03-31 | 886000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2025-12-31 | 435000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 430000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 860000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 430000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
Operating Segments · Non Us · Medication Delivery Solutions · Medical
Consolidation Items · Statement Geographical · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;bdx:OrganizationalUnitAxis=bdx:MedicationDeliverySolutionsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-10-01 – 2025-09-30 | 1787000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 452000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 1313000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 1768000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 453000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 1310000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
Operating Segments · Non Us · Medication Management Solutions · Connected Care
Consolidation Items · Statement Geographical · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;bdx:OrganizationalUnitAxis=bdx:MedicationManagementSolutionsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:ConnectedCareMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 168000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2026-03-31 | 324000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2025-12-31 | 156000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 149000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 291000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 142000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
Operating Segments · Non Us · Medication Management Solutions · Medical
Consolidation Items · Statement Geographical · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;bdx:OrganizationalUnitAxis=bdx:MedicationManagementSolutionsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-10-01 – 2025-09-30 | 664000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 179000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 470000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 670000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 160000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 475000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
Operating Segments · Non Us · Peripheral Intervention · Interventional
Consolidation Items · Statement Geographical · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;bdx:OrganizationalUnitAxis=bdx:PeripheralInterventionMember;us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 236000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2026-03-31 | 456000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2025-12-31 | 220000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2024-10-01 – 2025-09-30 | 929000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 241000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 673000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 212000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 432000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 220000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 904000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 225000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 669000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
Operating Segments · Non Us · Pharmaceutical Systems · Medical
Consolidation Items · Statement Geographical · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;bdx:OrganizationalUnitAxis=bdx:PharmaceuticalSystemsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-10-01 – 2025-09-30 | 1666000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 451000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 1191000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 1644000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 437000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 1154000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
Operating Segments · Non Us · Specimen Management · Life Sciences
Consolidation Items · Statement Geographical · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;bdx:OrganizationalUnitAxis=bdx:SpecimenManagementMember;us-gaap:StatementBusinessSegmentsAxis=bdx:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-10-01 – 2025-09-30 | 890000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 230000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 667000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 882000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 228000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 664000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
Operating Segments · Non Us · Specimen Management · Medical Essentials
Consolidation Items · Statement Geographical · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;bdx:OrganizationalUnitAxis=bdx:SpecimenManagementMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalEssentialsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 231000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2026-03-31 | 453000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2025-12-31 | 222000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 213000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 437000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 223000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
Operating Segments · Non Us · Surgery · Interventional
Consolidation Items · Statement Geographical · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;bdx:OrganizationalUnitAxis=bdx:SurgeryMember;us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 109000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2026-03-31 | 217000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2025-12-31 | 108000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2024-10-01 – 2025-09-30 | 397000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 101000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 288000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 94000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 187000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 92000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 363000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 93000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 273000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
Operating Segments · Non Us · Urologyand Critical Care · Interventional
Consolidation Items · Statement Geographical · Organizational Unit · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;bdx:OrganizationalUnitAxis=bdx:UrologyandCriticalCareMember;us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 79000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2026-03-31 | 167000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2025-12-31 | 88000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2024-10-01 – 2025-09-30 | 345000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 88000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 249000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 77000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 160000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 83000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 319000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 78000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 234000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
Operating Segments · Non Us · Connected Care
Consolidation Items · Statement Geographical · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:ConnectedCareMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 280000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2026-03-31 | 555000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2025-12-31 | 275000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 251000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 506000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 255000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
Operating Segments · Non Us · Interventional
Consolidation Items · Statement Geographical · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 423000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2026-03-31 | 839000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2025-12-31 | 416000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2024-10-01 – 2025-09-30 | 1671000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 430000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 1209000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 384000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 779000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 396000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 1586000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 396000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 1177000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
Operating Segments · Non Us · Life Sciences
Consolidation Items · Statement Geographical · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-10-01 – 2025-12-31 | 466000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2024-10-01 – 2025-09-30 | 2838000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 714000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 2081000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 470000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 2881000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 714000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 2139000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
Operating Segments · Non Us · Medical Essentials
Consolidation Items · Statement Geographical · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalEssentialsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-01-01 – 2026-03-31 | 682000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2026-03-31 | 1340000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2025-12-31 | 658000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 643000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 1297000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 654000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
Operating Segments · Non Us · Medical
Consolidation Items · Statement Geographical · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-10-01 – 2025-09-30 | 4540000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 1184000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 3290000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 4110000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 1050000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 2940000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
Operating Segments · Bio Pharma Systems
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:BioPharmaSystemsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 670000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-10-01 – 2026-06-30 | 1689000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 590000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2026-03-31 | 1019000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2025-12-31 | 429000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 629000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 1622000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 575000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 993000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 418000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
Operating Segments · Connected Care
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:ConnectedCareMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 1224000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-10-01 – 2026-06-30 | 3475000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 1120000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2026-03-31 | 2252000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2025-12-31 | 1131000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 1166000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 3307000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 1068000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 2141000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 1073000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
Operating Segments · Interventional
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 1414000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-10-01 – 2026-06-30 | 4101000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 1357000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2026-03-31 | 2687000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2025-12-31 | 1330000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2024-10-01 – 2025-09-30 | 5217000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 1328000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 3849000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 1264000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 2521000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 1257000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 4980000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 1240000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 3720000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
Operating Segments · Life Sciences
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-10-01 – 2025-12-31 | 766000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2024-10-01 – 2025-09-30 | 5167000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 1254000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 3798000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 1247000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 2545000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 836000000 Restated | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 5191000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 1260000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 3852000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
Operating Segments · Life Sciences · US
Consolidation Items · Statement Business Segments · Statement Geographical
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:LifeSciencesMember;srt:StatementGeographicalAxis=country:US| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-04-01 – 2024-06-30 | 546000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 1712000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
Operating Segments · Medical Essentials
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalEssentialsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 1675000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-10-01 – 2026-06-30 | 4918000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 1647000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2026-03-31 | 3242000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2025-10-01 – 2025-12-31 | 1595000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 1602000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 4760000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 1573000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 3158000000 | USD | 2026-05-07 · 20:34:32.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 1586000000 | USD | 2026-02-09 · 21:19:27.000Z | Open filing evidence |
Operating Segments · Medical
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-10-01 – 2025-09-30 | 11456000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 2927000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 8302000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 2760000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 5375000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 2615000000 | USD | 2025-02-06 · 22:03:32.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 10074000000 | USD | 2025-11-25 · 21:27:14.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 2558000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 7237000000 | USD | 2025-08-07 · 20:26:59.000Z | Open filing evidence |
Operating Segments · Medical · US
Consolidation Items · Statement Business Segments · Statement Geographical
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalMember;srt:StatementGeographicalAxis=country:US| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-04-01 – 2024-06-30 | 1508000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 4297000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
US · Advanced Patient Monitoring · Operating Segments · Medical
Statement Geographical · Organizational Unit · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;bdx:OrganizationalUnitAxis=bdx:AdvancedPatientMonitoringMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 155000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 314000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 47000000 | USD | 2024-11-27 · 18:36:08.000Z | Open filing evidence |
US · Biosciences · Operating Segments · Life Sciences
Statement Geographical · Organizational Unit · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;bdx:OrganizationalUnitAxis=bdx:BiosciencesMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 142000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 295000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 577000000 | USD | 2024-11-27 · 18:36:08.000Z | Open filing evidence |
US · Diagnostic Solutions · Operating Segments · Life Sciences
Statement Geographical · Organizational Unit · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;bdx:OrganizationalUnitAxis=bdx:DiagnosticSolutionsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 189000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 402000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
US · Integrated Diagnostic Solutions · Operating Segments · Life Sciences
Statement Geographical · Organizational Unit · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;bdx:OrganizationalUnitAxis=bdx:IntegratedDiagnosticSolutionsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-10-01 – 2024-09-30 | 1733000000 | USD | 2024-11-27 · 18:36:08.000Z | Open filing evidence |
US · Medication Delivery Solutions · Operating Segments · Medical
Statement Geographical · Organizational Unit · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;bdx:OrganizationalUnitAxis=bdx:MedicationDeliverySolutionsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 687000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 1381000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 2661000000 | USD | 2024-11-27 · 18:36:08.000Z | Open filing evidence |
US · Medication Management Solutions · Operating Segments · Medical
Statement Geographical · Organizational Unit · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;bdx:OrganizationalUnitAxis=bdx:MedicationManagementSolutionsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 662000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 1321000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 2627000000 | USD | 2024-11-27 · 18:36:08.000Z | Open filing evidence |
US · Peripheral Intervention · Operating Segments · Interventional
Statement Geographical · Organizational Unit · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;bdx:OrganizationalUnitAxis=bdx:PeripheralInterventionMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 269000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 522000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 1029000000 | USD | 2024-11-27 · 18:36:08.000Z | Open filing evidence |
US · Pharmaceutical Systems · Operating Segments · Medical
Statement Geographical · Organizational Unit · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;bdx:OrganizationalUnitAxis=bdx:PharmaceuticalSystemsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 149000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 253000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 629000000 | USD | 2024-11-27 · 18:36:08.000Z | Open filing evidence |
US · Specimen Management · Operating Segments · Life Sciences
Statement Geographical · Organizational Unit · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;bdx:OrganizationalUnitAxis=bdx:SpecimenManagementMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 242000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 481000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
US · Surgery · Operating Segments · Interventional
Statement Geographical · Organizational Unit · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;bdx:OrganizationalUnitAxis=bdx:SurgeryMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 289000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 591000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 1130000000 | USD | 2024-11-27 · 18:36:08.000Z | Open filing evidence |
US · Urologyand Critical Care · Operating Segments · Interventional
Statement Geographical · Organizational Unit · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;bdx:OrganizationalUnitAxis=bdx:UrologyandCriticalCareMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 323000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 629000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 1236000000 | USD | 2024-11-27 · 18:36:08.000Z | Open filing evidence |
US · Operating Segments · Advanced Patient Monitoring · Medical
Statement Geographical · Consolidation Items · Organizational Unit · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:AdvancedPatientMonitoringMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-10-01 – 2024-12-31 | 159000000 | USD | 2025-02-06 · 22:03:32.000Z | Open filing evidence |
US · Operating Segments · Biosciences · Life Sciences
Statement Geographical · Consolidation Items · Organizational Unit · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:BiosciencesMember;us-gaap:StatementBusinessSegmentsAxis=bdx:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-10-01 – 2024-12-31 | 153000000 | USD | 2025-02-06 · 22:03:32.000Z | Open filing evidence |
US · Operating Segments · Diagnostic Solutions · Life Sciences
Statement Geographical · Consolidation Items · Organizational Unit · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:DiagnosticSolutionsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-10-01 – 2024-12-31 | 212000000 | USD | 2025-02-06 · 22:03:32.000Z | Open filing evidence |
US · Operating Segments · Medication Delivery Solutions · Medical
Statement Geographical · Consolidation Items · Organizational Unit · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:MedicationDeliverySolutionsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-10-01 – 2024-12-31 | 694000000 | USD | 2025-02-06 · 22:03:32.000Z | Open filing evidence |
US · Operating Segments · Medication Management Solutions · Medical
Statement Geographical · Consolidation Items · Organizational Unit · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:MedicationManagementSolutionsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-10-01 – 2024-12-31 | 659000000 | USD | 2025-02-06 · 22:03:32.000Z | Open filing evidence |
US · Operating Segments · Peripheral Intervention · Interventional
Statement Geographical · Consolidation Items · Organizational Unit · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:PeripheralInterventionMember;us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-10-01 – 2024-12-31 | 253000000 | USD | 2025-02-06 · 22:03:32.000Z | Open filing evidence |
US · Operating Segments · Pharmaceutical Systems · Medical
Statement Geographical · Consolidation Items · Organizational Unit · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:PharmaceuticalSystemsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-10-01 – 2024-12-31 | 104000000 | USD | 2025-02-06 · 22:03:32.000Z | Open filing evidence |
US · Operating Segments · Specimen Management · Life Sciences
Statement Geographical · Consolidation Items · Organizational Unit · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:SpecimenManagementMember;us-gaap:StatementBusinessSegmentsAxis=bdx:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-10-01 – 2024-12-31 | 238000000 | USD | 2025-02-06 · 22:03:32.000Z | Open filing evidence |
US · Operating Segments · Surgery · Interventional
Statement Geographical · Consolidation Items · Organizational Unit · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:SurgeryMember;us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-10-01 – 2024-12-31 | 303000000 | USD | 2025-02-06 · 22:03:32.000Z | Open filing evidence |
US · Operating Segments · Urologyand Critical Care · Interventional
Statement Geographical · Consolidation Items · Organizational Unit · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:UrologyandCriticalCareMember;us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-10-01 – 2024-12-31 | 306000000 | USD | 2025-02-06 · 22:03:32.000Z | Open filing evidence |
US · Operating Segments · Interventional
Statement Geographical · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 880000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 1742000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 861000000 | USD | 2025-02-06 · 22:03:32.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 3394000000 | USD | 2024-11-27 · 18:36:08.000Z | Open filing evidence |
US · Operating Segments · Life Sciences
Statement Geographical · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 574000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 1178000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 603000000 | USD | 2025-02-06 · 22:03:32.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 2310000000 | USD | 2024-11-27 · 18:36:08.000Z | Open filing evidence |
US · Operating Segments · Medical
Statement Geographical · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=country:US;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 1653000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 3268000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 1615000000 | USD | 2025-02-06 · 22:03:32.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 5964000000 | USD | 2024-11-27 · 18:36:08.000Z | Open filing evidence |
US · Bio Pharma Systems · Bio Pharma Systems · Operating Segments
Statement Geographical · Statement Business Segments · Organizational Unit · Consolidation Items
Source dimensions
srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=bdx:BioPharmaSystemsMember;bdx:OrganizationalUnitAxis=bdx:BioPharmaSystemsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 204000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-10-01 – 2026-06-30 | 532000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 178000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 431000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
US · Connected Care · Advanced Patient Monitoring · Operating Segments
Statement Geographical · Statement Business Segments · Organizational Unit · Consolidation Items
Source dimensions
srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=bdx:ConnectedCareMember;bdx:OrganizationalUnitAxis=bdx:AdvancedPatientMonitoringMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 189000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-10-01 – 2026-06-30 | 547000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 176000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 490000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
US · Connected Care · Medication Management Solutions · Operating Segments
Statement Geographical · Statement Business Segments · Organizational Unit · Consolidation Items
Source dimensions
srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=bdx:ConnectedCareMember;bdx:OrganizationalUnitAxis=bdx:MedicationManagementSolutionsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 737000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-10-01 – 2026-06-30 | 2076000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 709000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 2030000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
US · Connected Care · Operating Segments
Statement Geographical · Statement Business Segments · Consolidation Items
Source dimensions
srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=bdx:ConnectedCareMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 926000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-10-01 – 2026-06-30 | 2623000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 885000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 2520000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
US · Interventional · Peripheral Intervention · Operating Segments
Statement Geographical · Statement Business Segments · Organizational Unit · Consolidation Items
Source dimensions
srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember;bdx:OrganizationalUnitAxis=bdx:PeripheralInterventionMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 294000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-10-01 – 2026-06-30 | 839000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 271000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 793000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
US · Interventional · Surgery · Operating Segments
Statement Geographical · Statement Business Segments · Organizational Unit · Consolidation Items
Source dimensions
srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember;bdx:OrganizationalUnitAxis=bdx:SurgeryMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 306000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-10-01 – 2026-06-30 | 919000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 294000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 885000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
US · Interventional · Urologyand Critical Care · Operating Segments
Statement Geographical · Statement Business Segments · Organizational Unit · Consolidation Items
Source dimensions
srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember;bdx:OrganizationalUnitAxis=bdx:UrologyandCriticalCareMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 357000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-10-01 – 2026-06-30 | 1047000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 334000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 962000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
US · Interventional · Operating Segments
Statement Geographical · Statement Business Segments · Consolidation Items
Source dimensions
srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 957000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-10-01 – 2026-06-30 | 2805000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 898000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 2640000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
US · Medical Essentials · Medication Delivery Solutions · Operating Segments
Statement Geographical · Statement Business Segments · Organizational Unit · Consolidation Items
Source dimensions
srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalEssentialsMember;bdx:OrganizationalUnitAxis=bdx:MedicationDeliverySolutionsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 720000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-10-01 – 2026-06-30 | 2124000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 680000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 2060000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
US · Medical Essentials · Specimen Management · Operating Segments
Statement Geographical · Statement Business Segments · Organizational Unit · Consolidation Items
Source dimensions
srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalEssentialsMember;bdx:OrganizationalUnitAxis=bdx:SpecimenManagementMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 274000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-10-01 – 2026-06-30 | 772000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 240000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 721000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
US · Medical Essentials · Operating Segments
Statement Geographical · Statement Business Segments · Consolidation Items
Source dimensions
srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalEssentialsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 994000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-10-01 – 2026-06-30 | 2897000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 920000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 2781000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
Non Us · Advanced Patient Monitoring · Operating Segments · Medical
Statement Geographical · Organizational Unit · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=us-gaap:NonUsMember;bdx:OrganizationalUnitAxis=bdx:AdvancedPatientMonitoringMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 102000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 215000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 27000000 | USD | 2024-11-27 · 18:36:08.000Z | Open filing evidence |
Non Us · Biosciences · Operating Segments · Life Sciences
Statement Geographical · Organizational Unit · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=us-gaap:NonUsMember;bdx:OrganizationalUnitAxis=bdx:BiosciencesMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 209000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 418000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 935000000 | USD | 2024-11-27 · 18:36:08.000Z | Open filing evidence |
Non Us · Diagnostic Solutions · Operating Segments · Life Sciences
Statement Geographical · Organizational Unit · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=us-gaap:NonUsMember;bdx:OrganizationalUnitAxis=bdx:DiagnosticSolutionsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 250000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 512000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
Non Us · Integrated Diagnostic Solutions · Operating Segments · Life Sciences
Statement Geographical · Organizational Unit · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=us-gaap:NonUsMember;bdx:OrganizationalUnitAxis=bdx:IntegratedDiagnosticSolutionsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-10-01 – 2024-09-30 | 1946000000 | USD | 2024-11-27 · 18:36:08.000Z | Open filing evidence |
Non Us · Medication Delivery Solutions · Operating Segments · Medical
Statement Geographical · Organizational Unit · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=us-gaap:NonUsMember;bdx:OrganizationalUnitAxis=bdx:MedicationDeliverySolutionsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 430000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 860000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 1768000000 | USD | 2024-11-27 · 18:36:08.000Z | Open filing evidence |
Non Us · Medication Management Solutions · Operating Segments · Medical
Statement Geographical · Organizational Unit · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=us-gaap:NonUsMember;bdx:OrganizationalUnitAxis=bdx:MedicationManagementSolutionsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 149000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 291000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 670000000 | USD | 2024-11-27 · 18:36:08.000Z | Open filing evidence |
Non Us · Peripheral Intervention · Operating Segments · Interventional
Statement Geographical · Organizational Unit · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=us-gaap:NonUsMember;bdx:OrganizationalUnitAxis=bdx:PeripheralInterventionMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 212000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 432000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 904000000 | USD | 2024-11-27 · 18:36:08.000Z | Open filing evidence |
Non Us · Pharmaceutical Systems · Operating Segments · Medical
Statement Geographical · Organizational Unit · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=us-gaap:NonUsMember;bdx:OrganizationalUnitAxis=bdx:PharmaceuticalSystemsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 426000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 740000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 1644000000 | USD | 2024-11-27 · 18:36:08.000Z | Open filing evidence |
Non Us · Specimen Management · Operating Segments · Life Sciences
Statement Geographical · Organizational Unit · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=us-gaap:NonUsMember;bdx:OrganizationalUnitAxis=bdx:SpecimenManagementMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 213000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 437000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
Non Us · Surgery · Operating Segments · Interventional
Statement Geographical · Organizational Unit · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=us-gaap:NonUsMember;bdx:OrganizationalUnitAxis=bdx:SurgeryMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 94000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 187000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 363000000 | USD | 2024-11-27 · 18:36:08.000Z | Open filing evidence |
Non Us · Urologyand Critical Care · Operating Segments · Interventional
Statement Geographical · Organizational Unit · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=us-gaap:NonUsMember;bdx:OrganizationalUnitAxis=bdx:UrologyandCriticalCareMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 77000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 160000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 319000000 | USD | 2024-11-27 · 18:36:08.000Z | Open filing evidence |
Non Us · Operating Segments · Advanced Patient Monitoring · Medical
Statement Geographical · Consolidation Items · Organizational Unit · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:AdvancedPatientMonitoringMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-10-01 – 2024-12-31 | 113000000 | USD | 2025-02-06 · 22:03:32.000Z | Open filing evidence |
Non Us · Operating Segments · Biosciences · Life Sciences
Statement Geographical · Consolidation Items · Organizational Unit · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:BiosciencesMember;us-gaap:StatementBusinessSegmentsAxis=bdx:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-10-01 – 2024-12-31 | 208000000 | USD | 2025-02-06 · 22:03:32.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 222000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 689000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
Non Us · Operating Segments · Diagnostic Solutions · Life Sciences
Statement Geographical · Consolidation Items · Organizational Unit · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:DiagnosticSolutionsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-10-01 – 2024-12-31 | 262000000 | USD | 2025-02-06 · 22:03:32.000Z | Open filing evidence |
Non Us · Operating Segments · Integrated Diagnostic Solutions · Life Sciences
Statement Geographical · Consolidation Items · Organizational Unit · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:IntegratedDiagnosticSolutionsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-04-01 – 2024-06-30 | 491000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 1451000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
Non Us · Operating Segments · Medication Delivery Solutions · Medical
Statement Geographical · Consolidation Items · Organizational Unit · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:MedicationDeliverySolutionsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-10-01 – 2024-12-31 | 430000000 | USD | 2025-02-06 · 22:03:32.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 453000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 1310000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
Non Us · Operating Segments · Medication Management Solutions · Medical
Statement Geographical · Consolidation Items · Organizational Unit · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:MedicationManagementSolutionsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-10-01 – 2024-12-31 | 142000000 | USD | 2025-02-06 · 22:03:32.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 160000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 475000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
Non Us · Operating Segments · Peripheral Intervention · Interventional
Statement Geographical · Consolidation Items · Organizational Unit · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:PeripheralInterventionMember;us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-10-01 – 2024-12-31 | 220000000 | USD | 2025-02-06 · 22:03:32.000Z | Open filing evidence |
Non Us · Operating Segments · Pharmaceutical Systems · Medical
Statement Geographical · Consolidation Items · Organizational Unit · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:PharmaceuticalSystemsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-10-01 – 2024-12-31 | 314000000 | USD | 2025-02-06 · 22:03:32.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 437000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 1154000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
Non Us · Operating Segments · Specimen Management · Life Sciences
Statement Geographical · Consolidation Items · Organizational Unit · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:SpecimenManagementMember;us-gaap:StatementBusinessSegmentsAxis=bdx:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-10-01 – 2024-12-31 | 223000000 | USD | 2025-02-06 · 22:03:32.000Z | Open filing evidence |
Non Us · Operating Segments · Surgery · Interventional
Statement Geographical · Consolidation Items · Organizational Unit · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:SurgeryMember;us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-10-01 – 2024-12-31 | 92000000 | USD | 2025-02-06 · 22:03:32.000Z | Open filing evidence |
Non Us · Operating Segments · Urologyand Critical Care · Interventional
Statement Geographical · Consolidation Items · Organizational Unit · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:UrologyandCriticalCareMember;us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-10-01 – 2024-12-31 | 83000000 | USD | 2025-02-06 · 22:03:32.000Z | Open filing evidence |
Non Us · Operating Segments · Interventional
Statement Geographical · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 384000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 779000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 396000000 | USD | 2025-02-06 · 22:03:32.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 1586000000 | USD | 2024-11-27 · 18:36:08.000Z | Open filing evidence |
Non Us · Operating Segments · Life Sciences
Statement Geographical · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:LifeSciencesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 673000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 1367000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 694000000 | USD | 2025-02-06 · 22:03:32.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 2881000000 | USD | 2024-11-27 · 18:36:08.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 714000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 2139000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
Non Us · Operating Segments · Medical
Statement Geographical · Consolidation Items · Statement Business Segments
Source dimensions
srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 1107000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2025-03-31 | 2107000000 | USD | 2025-05-01 · 20:30:56.000Z | Open filing evidence |
| 2024-10-01 – 2024-12-31 | 999000000 | USD | 2025-02-06 · 22:03:32.000Z | Open filing evidence |
| 2023-10-01 – 2024-09-30 | 4110000000 | USD | 2024-11-27 · 18:36:08.000Z | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 1050000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 2940000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
Non Us · Bio Pharma Systems · Bio Pharma Systems · Operating Segments
Statement Geographical · Statement Business Segments · Organizational Unit · Consolidation Items
Source dimensions
srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:BioPharmaSystemsMember;bdx:OrganizationalUnitAxis=bdx:BioPharmaSystemsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 467000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-10-01 – 2026-06-30 | 1157000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 451000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 1191000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
Non Us · Connected Care · Advanced Patient Monitoring · Operating Segments
Statement Geographical · Statement Business Segments · Organizational Unit · Consolidation Items
Source dimensions
srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:ConnectedCareMember;bdx:OrganizationalUnitAxis=bdx:AdvancedPatientMonitoringMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 120000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-10-01 – 2026-06-30 | 350000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 102000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 317000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
Non Us · Connected Care · Medication Management Solutions · Operating Segments
Statement Geographical · Statement Business Segments · Organizational Unit · Consolidation Items
Source dimensions
srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:ConnectedCareMember;bdx:OrganizationalUnitAxis=bdx:MedicationManagementSolutionsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 178000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-10-01 – 2026-06-30 | 502000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 179000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 470000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
Non Us · Connected Care · Operating Segments
Statement Geographical · Statement Business Segments · Consolidation Items
Source dimensions
srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:ConnectedCareMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 297000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-10-01 – 2026-06-30 | 852000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 281000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 787000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
Non Us · Interventional · Peripheral Intervention · Operating Segments
Statement Geographical · Statement Business Segments · Organizational Unit · Consolidation Items
Source dimensions
srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember;bdx:OrganizationalUnitAxis=bdx:PeripheralInterventionMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 258000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-10-01 – 2026-06-30 | 713000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 241000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 673000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
Non Us · Interventional · Surgery · Operating Segments
Statement Geographical · Statement Business Segments · Organizational Unit · Consolidation Items
Source dimensions
srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember;bdx:OrganizationalUnitAxis=bdx:SurgeryMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 116000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-10-01 – 2026-06-30 | 333000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 101000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 288000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
Non Us · Interventional · Urologyand Critical Care · Operating Segments
Statement Geographical · Statement Business Segments · Organizational Unit · Consolidation Items
Source dimensions
srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember;bdx:OrganizationalUnitAxis=bdx:UrologyandCriticalCareMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 82000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-10-01 – 2026-06-30 | 250000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 88000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 249000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
Non Us · Interventional · Operating Segments
Statement Geographical · Statement Business Segments · Consolidation Items
Source dimensions
srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 457000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-10-01 – 2026-06-30 | 1296000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 430000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 1209000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
Non Us · Medical Essentials · Medication Delivery Solutions · Operating Segments
Statement Geographical · Statement Business Segments · Organizational Unit · Consolidation Items
Source dimensions
srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalEssentialsMember;bdx:OrganizationalUnitAxis=bdx:MedicationDeliverySolutionsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 444000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-10-01 – 2026-06-30 | 1331000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 452000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 1313000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
Non Us · Medical Essentials · Specimen Management · Operating Segments
Statement Geographical · Statement Business Segments · Organizational Unit · Consolidation Items
Source dimensions
srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalEssentialsMember;bdx:OrganizationalUnitAxis=bdx:SpecimenManagementMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 237000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-10-01 – 2026-06-30 | 690000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 230000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 667000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
Non Us · Medical Essentials · Operating Segments
Statement Geographical · Statement Business Segments · Consolidation Items
Source dimensions
srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalEssentialsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 681000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-10-01 – 2026-06-30 | 2021000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 682000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 1979000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
Bio Pharma Systems · Bio Pharma Systems · Operating Segments
Statement Business Segments · Organizational Unit · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=bdx:BioPharmaSystemsMember;bdx:OrganizationalUnitAxis=bdx:BioPharmaSystemsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 670000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-10-01 – 2026-06-30 | 1689000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 629000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 1622000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
Connected Care · Advanced Patient Monitoring · Operating Segments
Statement Business Segments · Organizational Unit · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=bdx:ConnectedCareMember;bdx:OrganizationalUnitAxis=bdx:AdvancedPatientMonitoringMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 309000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-10-01 – 2026-06-30 | 897000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 278000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 806000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
Connected Care · Medication Management Solutions · Operating Segments
Statement Business Segments · Organizational Unit · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=bdx:ConnectedCareMember;bdx:OrganizationalUnitAxis=bdx:MedicationManagementSolutionsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 915000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-10-01 – 2026-06-30 | 2578000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 888000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 2500000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
Interventional · Peripheral Intervention · Operating Segments
Statement Business Segments · Organizational Unit · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember;bdx:OrganizationalUnitAxis=bdx:PeripheralInterventionMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 552000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-10-01 – 2026-06-30 | 1552000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 512000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 1466000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
Interventional · Surgery · Operating Segments
Statement Business Segments · Organizational Unit · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember;bdx:OrganizationalUnitAxis=bdx:SurgeryMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 422000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-10-01 – 2026-06-30 | 1252000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 395000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 1173000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
Interventional · Urologyand Critical Care · Operating Segments
Statement Business Segments · Organizational Unit · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember;bdx:OrganizationalUnitAxis=bdx:UrologyandCriticalCareMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 440000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-10-01 – 2026-06-30 | 1297000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 422000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 1211000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
Interventional · Operating Segments
Statement Business Segments · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-04-01 – 2024-06-30 | 1240000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 3720000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
Interventional · Operating Segments · Peripheral Intervention
Statement Business Segments · Consolidation Items · Organizational Unit
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:PeripheralInterventionMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-04-01 – 2024-06-30 | 488000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 1431000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
Interventional · Operating Segments · Peripheral Intervention · US
Statement Business Segments · Consolidation Items · Organizational Unit · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:PeripheralInterventionMember;srt:StatementGeographicalAxis=country:US| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-04-01 – 2024-06-30 | 263000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 762000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
Interventional · Operating Segments · Surgery
Statement Business Segments · Consolidation Items · Organizational Unit
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:SurgeryMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-04-01 – 2024-06-30 | 376000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 1124000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
Interventional · Operating Segments · Surgery · US
Statement Business Segments · Consolidation Items · Organizational Unit · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:SurgeryMember;srt:StatementGeographicalAxis=country:US| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-04-01 – 2024-06-30 | 283000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 851000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
Interventional · Operating Segments · Urologyand Critical Care
Statement Business Segments · Consolidation Items · Organizational Unit
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:UrologyandCriticalCareMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-04-01 – 2024-06-30 | 375000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 1165000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
Interventional · Operating Segments · Urologyand Critical Care · US
Statement Business Segments · Consolidation Items · Organizational Unit · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:UrologyandCriticalCareMember;srt:StatementGeographicalAxis=country:US| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-04-01 – 2024-06-30 | 297000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 930000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
Interventional · Operating Segments · US
Statement Business Segments · Consolidation Items · Statement Geographical
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:StatementGeographicalAxis=country:US| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-04-01 – 2024-06-30 | 844000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 2543000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
Interventional · Non Us · Operating Segments
Statement Business Segments · Statement Geographical · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-04-01 – 2024-06-30 | 396000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 1177000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
Interventional · Non Us · Operating Segments · Peripheral Intervention
Statement Business Segments · Statement Geographical · Consolidation Items · Organizational Unit
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:PeripheralInterventionMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-04-01 – 2024-06-30 | 225000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 669000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
Interventional · Non Us · Operating Segments · Surgery
Statement Business Segments · Statement Geographical · Consolidation Items · Organizational Unit
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:SurgeryMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-04-01 – 2024-06-30 | 93000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 273000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
Interventional · Non Us · Operating Segments · Urologyand Critical Care
Statement Business Segments · Statement Geographical · Consolidation Items · Organizational Unit
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=bdx:InterventionalMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;bdx:OrganizationalUnitAxis=bdx:UrologyandCriticalCareMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-04-01 – 2024-06-30 | 78000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
| 2023-10-01 – 2024-06-30 | 234000000 | USD | 2024-08-01 · 20:33:44.000Z | Open filing evidence |
Medical Essentials · Medication Delivery Solutions · Operating Segments
Statement Business Segments · Organizational Unit · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalEssentialsMember;bdx:OrganizationalUnitAxis=bdx:MedicationDeliverySolutionsMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 1164000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-10-01 – 2026-06-30 | 3455000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 1132000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 3373000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
Medical Essentials · Specimen Management · Operating Segments
Statement Business Segments · Organizational Unit · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=bdx:MedicalEssentialsMember;bdx:OrganizationalUnitAxis=bdx:SpecimenManagementMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 511000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-10-01 – 2026-06-30 | 1463000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 470000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |
| 2024-10-01 – 2025-06-30 | 1387000000 | USD | 2026-08-06 · 20:36:58.000Z | Open filing evidence |